Takeda's R&D team applies AI to some of its hardest scientific questions, from indication expansion to mechanism of action discovery. In this on demand fireside chat, Vinayagam Arunachalam, Senior Director and Head of Computational and Systems Biology at Takeda, joins Joe Gigliotti of Causaly for a conversation hosted by Pharmaceutical Executive and moderated by Megan Manzano.

What you will learn

• How Takeda decided to invest in a purpose built scientific AI platform instead of a general LLM
• A real R&D use case, including a project that narrowed 65 candidate indications to 10 in one month
• How computational biologists and wet lab scientists at Takeda found a shared way of working with AI
• What it takes to scale AI from a pilot to everyday practice across R&D teams
• Vinu's advice for R&D leaders who are just starting to deploy AI

Speakers

Vinayagam Arunachalam

‍Senior Director, Head of Computational and Systems Biology, Takeda

Leads target identification, biomarker discovery, and disease pathway analysis for Takeda's GI² Early Clinical Development unit. Brings more than 18 years of experience across Pfizer, Harvard Medical School, and the German Cancer Research Center.

Joe Gigliotti, MD, MBA

Strategic Client Partner, Causaly

Megan Manzano

‍Moderator, Pharmaceutical Executive